Anthropic Inc. is set to make its Nasdaq debut on Thursday, offering Canadian investors a variety of new investment products to gain exposure to the AI company. While the initial public offering (IPO) price is US$83 per share, Canadians can now choose from several alternatives, including exchange-traded funds (ETFs) with leverage and covered-call strategies, as well as Canadian Depositary Receipts (CDRs). These products aim to provide different trade-offs for investors, though recent performance of similar offerings, like SpaceX shares, highlights the risks of investing in newly listed companies.
CIBC Capital Markets and Bank of Montreal are introducing Anthropic CDRs, which will trade on the TSX under the ticker ANTH. Each CDR initially represents a quarter of an Anthropic Nasdaq share, with adjustments based on the Canadian-U.S. dollar exchange rate. These instruments come with a hedging fee but reduce currency risk for investors. Elliot Scherer, global head of the Wealth Solutions Group at CIBC Capital Markets, emphasized that these products cater to investor demand for Canadian-dollar-denominated exposure to global companies.
Harvest ETFs is launching the Harvest Anthropic Enhanced High Income Shares ETF (ANTE), a single-stock ETF that will hold Anthropic shares with 25-per-cent leverage and apply a covered-call strategy on up to half of the portfolio. Avinash D’Souza, vice-president of product strategy at Harvest ETFs, noted that similar products linked to SpaceX have seen significant uptake, with nearly a quarter of a billion dollars in net new money since June. However, he acknowledged the risks associated with these ETFs, including capped upside and magnified losses due to leverage.
Financial experts caution investors about the excitement surrounding the Anthropic IPO. Jason Heath, managing director at Objective Financial Partners, advised caution, noting that a successful company does not always translate to a successful investment. He suggested that while there may be a place for Anthropic in a portfolio, investors should avoid overconcentration in any single stock.